(ADMA) ADMA Biologics - Ratings and Ratios

ADMA Biologics Inc. is a biopharmaceutical company specializing in the development, manufacture, and marketing of plasma-derived biologics for treating immune deficiencies and infectious diseases. The companys product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) products for primary humoral immunodeficiency (PI), and Nabi-HB, a human polyclonal antibody for treating Hepatitis B exposure. ADMA Biologics operates plasma collection facilities and distributes its products through various channels, including independent distributors and specialty pharmacies.

With a strong presence in the biotechnology sector, ADMA Biologics has shown significant growth potential. The companys pipeline includes plasma-derived therapeutics for preventing and treating S. pneumonia infections. As a leading player in the specialty plasma-derived biologics market, ADMA Biologics is poised for expansion, driven by increasing demand for its products and a robust pipeline.

Analyzing the technical data, ADMA Biologics stock is currently trading at $20.61, above its 20-day Simple Moving Average (SMA) of $20.04 and below its 50-day SMA of $20.71. The stock has shown a relatively stable trend, with an Average True Range (ATR) of 1.10, indicating a volatility of 5.36%. Given the current support and resistance levels, a potential breakout above the resistance level of $22.2 could signal a bullish trend.

From a fundamental perspective, ADMA Biologics has a market capitalization of $4853.46M USD, with a Price-to-Earnings (P/E) ratio of 24.20 and a forward P/E of 28.99. The companys Return on Equity (RoE) stands at 72.39%, indicating strong profitability. Considering these fundamental indicators and the technical data, a forecast for ADMA Biologics suggests a potential price target of $25-$28 in the next 6-12 months, driven by the companys growth prospects, pipeline expansion, and increasing demand for its products.

Based on the analysis, the forecast suggests that ADMA Biologics is likely to experience a price increase as it continues to execute on its growth strategy, expand its product portfolio, and capitalize on the growing demand for specialty plasma-derived biologics. Investors should monitor the stocks performance, particularly its ability to break through the resistance level of $22.2, and adjust their strategies accordingly.